This is a UK news story, published by Nature, that relates primarily to Moderna news.
For more UK news, you can click here:
more UK newsFor more Moderna news, you can click here:
more Moderna newsFor more vaccine development news, you can click here:
more vaccine development newsFor more news from Nature, you can click here:
more news from NatureOtherweb, Inc is a public benefit corporation, dedicated to improving the quality of news people consume. We are non-partisan, junk-free, and ad-free. We use artificial intelligence (AI) to remove junk from your news feed, and allow you to select the best health news, business news, entertainment news, and much more. If you like this article about vaccine development, you might also like this article about
seasonal influenza vaccine. We are dedicated to bringing you the highest-quality news, junk-free and ad-free, about your favorite topics. Please come every day to read the latest multicomponent vaccine news, influenza vaccine news, news about vaccine development, and other high-quality news about any topic that interests you. We are working hard to create the best news aggregator on the web, and to put you in control of your news feed - whether you choose to read the latest news through our website, our news app, or our daily newsletter - all free!
influenza virus vaccinesNature
•Health
Health
86% Informative
mRNA-based multicomponent vaccine (mRNA-1083) encoding seasonal influenza and SARS-CoV-2 antigens.
The vaccine was generally well-tolerated, with most solicited adverse reactions being Grade 1 or 2 in severity.
The incidence of unsolicited adverse events was similar across vaccine groups.
Co-administration of influenza and COVID-19 vaccines: policy review and vaccination coverage trends in the European Union , UK , US , and Canada between 2019 and 2023 .
Moderna announces positive phase 3 efficacy data for mRNA-1283, the company’s next generation.
Fluarix Quadrivalent ( Influenza Vaccine ) injectable suspension, for intramuscular use—20232024. The study was funded by Moderna, Inc. , who had a role in study conceptualization/design, data collection, data analysis, preparation of the manuscript and decision to publish the results.
VR Score
93
Informative language
98
Neutral language
57
Article tone
formal
Language
English
Language complexity
60
Offensive language
not offensive
Hate speech
not hateful
Attention-grabbing headline
not detected
Known propaganda techniques
not detected
Time-value
long-living
External references
1
Source diversity
1
Affiliate links
no affiliate links
Small business owner?
